Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?

被引：0

作者：

Rossella E Nappi

Gabriele S Merki-Feld

Erica Terreno

Alice Pellegrinelli

Michele Viana

机构：

[1] IRCCS S. Matteo Foundation,Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause

[2] University of Pavia,Department of Clinical, Surgical, Diagnostic and Paediatric Sciences

[3] University Hospital Zürich,Clinic for Reproductive Endocrinology

[4] Headache Science Center - National Neurological Institute C. Mondino,Research Center for Reproductive Medicine, Unit of Obstetrics and Gynecology

[5] IRCCS Policlinico ‘San Matteo’,undefined

来源：

The Journal of Headache and Pain | 2013年 / 14卷

关键词：

Migraine with aura (MA); Migraine without aura (MO); Combined hormonal contraceptives (CHCs); Combined oral contraceptives (COCs); Progestogen-only contraception; Desogestrel-only pill; Venous thromboembolism (VTE); Stroke;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A significant number of women with migraine has to face the choice of reliable hormonal contraception during their fertile life. Combined hormonal contraceptives (CHCs) may be used in the majority of women with headache and migraine. However, they carry a small, but significant vascular risk, especially in migraine with aura (MA) and, eventually in migraine without aura (MO) with additional risk factors for stroke (smoking, hypertension, diabetes, hyperlipidemia and thrombophilia, age over 35 years). Guidelines recommend progestogen-only contraception as an alternative safer option because it does not seem to be associated with an increased risk of venous thromboembolism (VTE) and ischemic stroke.

引用

共 50 条

[41] Hormonal contraception in obese women
Bitzer, Johannes
[J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2016, 206 : 252 - 253
[42] Hormonal contraception in perimenopausal women
Tschuertz, Nikolai
Schaudig, Katrin
Bachmann, Annette
[J]. GYNAKOLOGISCHE ENDOKRINOLOGIE, 2024, 22 (01): : 68 - 74
[43] From Research to Policy: The WHO Experience With Developing Guidelines on the Potential Risk of HIV Acquisition and Progestogen-Only Contraception Use
Han, Leo
Patil, Eva
Kidula, Nancy
Gaffield, Mary Lyn
Steyn, Petrus S.
[J]. GLOBAL HEALTH-SCIENCE AND PRACTICE, 2017, 5 (04): : 540 - 546
[44] PROTECTIVE INFLUENCE OF PROGESTOGEN ONLY CONTRACEPTION AGAINST VAGINAL MONILIASIS
TOPPOZADA, M
ONSY, FA
FARES, E
AMIR, S
SHAALA, S
[J]. CONTRACEPTION, 1979, 20 (02) : 99 - 103
[45] ESTROGENIC ACTIVITY IN WOMEN RECEIVING AN INJECTABLE PROGESTOGEN FOR CONTRACEPTION
MISHELL, DR
THORNEYCROFT, IH
NAKAMURA, RM
KHARMA, KM
[J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1972, 113 (03) : 372 - +
[46] Cardiovacular risk of hormonal contraception in women
Christin-Maitre, Sophie
[J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2016, 200 (07): : 1485 - 1495
[47] Postpartum hormonal contraception in breastfeeding women
Stanton, Taylor A.
Blumenthal, Paul D.
[J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2019, 31 (06) : 441 - 446
[48] Safety of hormonal contraception for obese women
Rocha, Ana Luiza L.
Campos, Rayana R.
Miranda, Marina M. S.
Raspante, Laio B. P.
Carneiro, Marcia M.
Vieira, Carolina S.
Reis, Fernando M.
[J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) : 1387 - 1393
[49] The risk-benefit balance of estrogen-progestogen hormonal contraception
Plu-Bureau, Genevieve
Raccah-Tebeka, Brigitte
[J]. M S-MEDECINE SCIENCES, 2022, 38 (01): : 59 - 69
[50] Progestogen-only injectable contraceptive: Experience of women in Osogbo, southwestern Nigeria
Adeyemi, A. S.
Adekanle, D. A.
[J]. ANNALS OF AFRICAN MEDICINE, 2012, 11 (01) : 27 - 31

← 1 2 3 4 5 →